Alnylam Pharma (ALNY) Tops Q4 EPS by 46c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $291.37 -0.61%
Revenue Growth %: +70.6%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +70.6%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.39), $0.46 better than the analyst estimate of ($1.85). Revenue for the quarter came in at $335.04 million versus the consensus estimate of $312.2 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- Benchmark Reiterates Buy Rating on IMAX Corporation (IMAX), Highlights 'The Odyssey' Potential
- Orion Digital receives Nasdaq minimum bid price deficiency notice
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
